SSRIs take weeks and ketamine takes hours; the NU670 Unit 8 brief explains the gap through synaptic plasticity and labels each supporting finding by species and design. Searches like "nu 670 unit 8 assignment example", "nu670 unit 8 sample" and "nu670 unit 8 example" land here.
What a finished NU670 Unit 8 neuroplasticity brief looks like
Three pages with a timeline figure. The figure places two tracks against hours and weeks: SSRI transporter blockade within hours of the first dose, clinical change typically over several weeks; ketamine's NMDA blockade within minutes and mood change within hours for many trial participants. The prose then gives the leading plasticity account for each. For SSRIs, chronic treatment raises BDNF and TrkB signaling in rodent hippocampus and cortex, and slow synaptic remodeling is proposed to track the delayed response. For ketamine, the disinhibition hypothesis holds that blocking NMDA receptors on GABA interneurons releases a glutamate burst, activating AMPA receptors, BDNF release and mTORC1, which drives new dendritic spines in rat prefrontal cortex (Li et al., 2010). Moda-Sava et al. (2019) found in mice that new spines formed after the behavioral effect began and were needed to sustain it.
How a NU670 Unit 8 example is structured
The two composite starts open the brief because the contrast is the question; the patients do no further work after the first paragraph. The timeline figure comes next, and the prose beneath it keeps the two drugs in parallel so each claim about one has a counterpart about the other. Every mechanistic sentence ends with a bracketed evidence label, [rat], [mouse], [human trial] or [human imaging], and the brief notes where a claim has only the first two. A paragraph addresses rival accounts: hydroxynorketamine acting independently of NMDA blockade, and a proposal that antidepressants bind TrkB directly (Casarotto et al., 2021), both described as findings awaiting independent replication. The conclusion separates what can be said with confidence, that ketamine's clinical speed is established in human trials, from what cannot, that spine growth explains it in people. References follow the evidence labels.
Contrast as the question
Two composite adults starting treatment on one day frame the brief. Their different timelines supply the puzzle, and everything after the opening paragraph answers it without returning to them as case material.
Parallel tracks, parallel claims
Every statement about the SSRI has a counterpart about ketamine, on the figure and in the prose. Keeping the tracks parallel stops either drug from receiving a mechanism the other is silently denied.
Species on every line
Bracketed labels follow each mechanistic claim. It is plain at once that spine growth, mTORC1 signaling and BDNF release rest mainly on rat and mouse work, while the speed of response rests on human trials.
Spines that came second
The mouse finding that new spines appeared after the behavioral change, and maintained it, is reported carefully. It complicates the simplest story, in which synapse growth causes the first improvement.
Rivals given a paragraph
Hydroxynorketamine and direct TrkB binding are presented as live alternatives from single research groups. Naming them shows the plasticity account is leading but not settled, which is the position the evidence supports.
Where marks go in NU670 Unit 8
The largest deduction goes to neuroplasticity left as a label with nothing underneath it, a sentence saying ketamine promotes plasticity and SSRIs do so slowly, with no receptor, signaling pathway or structural change named. Presenting rodent spine data as if they had been observed in human patients comes a close second, since this course grades claim strength as heavily as content. Graders deduct for an SSRI delay explained only by rising serotonin, when transporter blockade occurs within hours and cannot account for the lag alone. Leaving out the mouse finding that spines followed the behavioral effect draws a comment about oversimplification. Any sentence recommending ketamine or esketamine for a patient, or discussing amounts, falls outside the assignment. Smaller losses come from treating esketamine and racemic ketamine as identical and from undated citations.
Get a NU670 Unit 8 example written to your instructions
Pass along the Unit 8 prompt your NU670 section set, with its rubric, and name the drugs involved if the prompt leaves that open. We write the first brief free to those instructions, back in 24-48h, with a timeline for each drug, the plasticity account traced link by link, and every mechanistic claim labeled with the species and design behind it.
NU670 Unit 8 questions, answered
Is the BDNF hypothesis of depression still accepted?
It remains influential but has been revised repeatedly. Rodent studies consistently show antidepressants raising BDNF signaling, while human evidence relies largely on blood measures and postmortem tissue, which are indirect. Present it as a leading framework with strong animal support and partial human support, and note where the field has moved toward network and synapse-level accounts.
Should the brief discuss psychedelics as well?
Not unless the prompt invites it. Psilocybin and related compounds are studied partly for plasticity effects, and a sentence noting that parallel may show range. Keeping the focus on the two timelines your prompt names usually produces a tighter argument than widening the brief to every rapidly acting agent under investigation.
How do esketamine and ketamine differ?
Esketamine is the S-enantiomer of racemic ketamine, approved by the FDA in 2019 as a nasal spray for treatment-resistant depression under a restricted program. Racemic ketamine is used off-label, usually intravenously. They share the NMDA mechanism but differ in regulatory status and in parts of their evidence base, so a brief should name which one each study used.